Immunovia AB (publ) (IMMNOV)
Free
No email, no account, no signup.
Pulling latest news for Immunovia AB (publ)…
Bull
Bear
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report – Signal
NEUTRAL
Sentiment
6/10
Risk
9/10
Get full analysis with Bull/Bear case, catalysts, and risk analysis
Buy express analysis –
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Sentiment has improved toward neutral following the published AFFIRM results and new performance data that strengthen the reimbursement narrative, though investors remain focused on very low revenues, potential funding needs, and US execution risk.
Exchange
Nasdaq Stockholm
Type
Biotech
Sector
Cancer diagnostics (blood test for pancreatic cancer)
Market Cap
$14M
Market sentiment
Sentiment has improved toward neutral following the published AFFIRM results and new performance data that strengthen the reimbursement narrative, though investors remain focused on very low revenues, potential funding needs, and US execution risk.
Why NEUTRAL ?
- **Promising clinical performance** and a clear addressable market.
- **Revenues remain minimal**, making the equity highly news-driven.
- **High execution risk** in U.S. reimbursement and adoption pathways.
- Estimated runway of ~**9 months** makes 2026 pivotal for traction.
- Wait/hold a small watch position until clear volume growth and improved coverage signals emerge.
Recent News
- Since the last analysis, Immunovia published final AFFIRM results in the Journal of Clinical Oncology (10 June 2026), supporting PancreaSure’s diagnostic performance. On 15 June 2026 the company released additional performance data (including 83.3% sensitivity and 91.6% specificity in symptomatic high-risk individuals), positioned to support an upcoming Medicare coverage submission (targeted for Q3 2026). The AGM on 13 May approved a new warrant incentive program, and Avanza crossed the 10% voting-rights threshold (6 May). The share has traded around SEK 0.18–0.21 with a clear volume spike around the news flow.
Bull case
- **Additional state approvals** could quickly expand commercial reach.
- Early **test orders/adoption** from centers could move the stock from depressed levels.
Unlock to read more →
Bear case
- **Low near-term revenue** may amplify funding concerns.
Unlock to read more →
Catalysts
1 Jul 2026 — Clinical utility/registry (~400 pts)
Dilution Risk
Assessment: Medium
Order analysis – $4.99 $1.25
Save hours of research. $4.99 $1.25.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Want to read the full analysis?
Order a fresh analysis of Immunovia AB (publ) – ready in your inbox in 5–15 minutes.
- Signal + risk + sentiment
- Bull/Bear case + triggers
- Catalysts with dates
- Saved as a webpage in your account
- Ready in 5–15 min (email when ready)
Full analysis at introductory pricing — 7-day money-back guarantee.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Fact-based analysis
Updated weekly
No commitment period
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.